Abstract:
Common systems for the quantification of cellular contraction rely on animal-based models, complex experimental setups or indirect approaches. Integration into standard lab procedures remains a challenge for current in vitro systems. The FLEXcyte 96 system has the potential to scale-up mechanical testing towards medium-throughput analyses. We show here that, using stem cell-derived cardiomyocytes, this system enables predictive recordings of contractile behaviour in the presence of well-known reference compounds.